Report cover image

Evaluating the Trump Administration’s New MFN Medicaid GENEROUS Model

Publisher GlobalData
Published Dec 19, 2025
Length 15 Pages
SKU # GBDT20830668

Description

Evaluating the Trump Administration’s New MFN Medicaid GENEROUS Model

Summary

Since the US president Donald Trump issued the Most Favored Nation (MFN) executive order, several pharmaceutical companies have agreed to comply with MFN pricing and more are expected to fall in line in the future. The Trump administration also recently revealed a new program for Medicaid, dubbed the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) model, where State Medicaid programs will be able to purchase drugs at MFN prices. The GENEROUS model revealed details on how international reference pricing (IRP) will be introduced into the US. GlobalData therefore examines the impact of this model for pharma companies.

Table of Contents

15 Pages
    • Progression of the MFN executive order so far
    • Details of the Medicaid GENEROUS model
    • Implementing MFN pricing to popular drugs used in Medicaid
    • Pharma industry response to MFN so far
    • Outlook and implications

Search Inside Report

How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.